Kazia Therapeutics
Sydney, New South Wales, Australia · Biotechnology, Health Care · 9 employees
Kazia Therapeutics is a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need. The company focuses on innovative drug development and is based in Sydney, Australia.
Funding history
- Funding Round — $55.3M — Dec 2025
- Series seed — $2.1M — Aug 2025
- Series seed — $2.0M — Aug 2025
- Series seed — $2.1M — Jan 2025
- Series seed — $2.0M — Dec 2023
Recent signals
- Jun 02, 2026: Kazia Therapeutics Appoints James Levine as Chief Financial Officer
- Apr 17, 2026: Acquired Kazia Therapeutics acquires QIMR Berghofer's therapy
- Apr 15, 2026: Kazia Therapeutics Appoints Dr. Sudha Rao as Chief Scientific Officer
- Dec 18, 2025: Raised $55.3M
- Aug 14, 2025: Raised $2.1M in Series seed
- Aug 01, 2025: Raised $2.0M in Series seed
- Jan 17, 2025: Raised $2.1M in Series seed
- Dec 15, 2023: Raised $2.0M in Series seed
See plans & pricing → Track Kazia Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.